News

Qubigen is thrilled to announce that we have been named the Gold winner in the Medical category of The Australian Financial Review AFR BOSS Most Innovative Companies Awards, taking out the top spot in this prestigious national competition. Read the full feature article in The Australian Financial Review. Pioneering Decentralized Intelligence in Drug Discovery While the headlines across the tech and biotech sectors continue to be dominated by massive frontier AI labs and centr

BIO 2026 in San Diego brought together a diverse cross-section of global biotechnology, pharmaceutical research, manufacturing and clinical organizations, providing a valuable snapshot of how artificial intelligence is being evaluated and adopted across the drug discovery landscape. Across four days of meetings and discussions, one message became increasingly clear: the conversation has shifted beyond whether AI merely has a role in drug discovery to how it can best deliver m

Qubigen is pleased to share encouraging progress from its ongoing collaboration with QIMR Berghofer. The partnership combines QIMR Berghofer’s expertise in translational cancer biology with Qubigen’s privacy-preserving Federated AI platform to identify novel small-molecule candidates targeting tumorigenesis and cancer progression. The project is now advancing from computational discovery and early experimental validation into the AI optimization and hit-to-lead acceleration p